ADC Therapeutics SA Increase Decrease Through Share-based Payment Transactions
ADC Therapeutics SA (ADCT) reported Increase Decrease Through Share-based Payment Transactions of $2.08 million for the 3-month period ending 2023-09-30, per its 6-K filed 2023-11-07.
Discontinued › Notes › Compensation Related Costs
ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions · last filed 2023-11-07
- ADC Therapeutics SA increase decrease through share-based payment transactions for the quarter ending 2023-09-30 was $2.08M, a 85.70% decline year-over-year.
- ADC Therapeutics SA increase decrease through share-based payment transactions for the quarter ending 2023-06-30 was $1.12M, a 91.91% decline year-over-year.
- ADC Therapeutics SA increase decrease through share-based payment transactions for the quarter ending 2023-03-31 was $8.07M, a 39.74% decline year-over-year.
- ADC Therapeutics SA increase decrease through share-based payment transactions for the quarter ending 2022-12-31 was $7.54M, a 43.99% decline year-over-year.
| Period end | Increase Decrease Through Share-based Payment Transactions 3 month | Increase Decrease Through Share-based Payment Transactions 6 month | Increase Decrease Through Share-based Payment Transactions 9 month | Increase Decrease Through Share-based Payment Transactions 12 month |
|---|---|---|---|---|
| 2023-09-30 | $2.08M 6-K · filed 2023-11-07 | $3.20M derived: sum of 2 quarters · filed 2023-11-07 | $11.28M 6-K · filed 2023-11-07 | $18.82M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | $1.12M 6-K · filed 2023-08-08 | $9.19M 6-K · filed 2023-08-08 | $16.73M derived: sum of 3 quarters · filed 2023-08-08 | $31.30M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-03-31 | $8.07M 6-K · filed 2023-05-09 | $15.62M derived: sum of 2 quarters · filed 2023-05-09 | $30.18M derived: sum of 3 quarters · filed 2023-11-07 | $44.00M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-12-31 | $7.54M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $22.11M derived: sum of 2 quarters · filed 2023-11-07 | $35.92M derived: sum of 3 quarters · filed 2023-11-07 | $49.32M 20-F · filed 2023-03-15 |
| 2022-09-30 | $14.56M 6-K · filed 2023-11-07 | $28.38M derived: sum of 2 quarters · filed 2023-11-07 | $41.78M 6-K · filed 2023-11-07 | $55.24M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $13.82M 6-K · filed 2023-08-08 | $27.22M 6-K · filed 2023-08-08 | $40.68M derived: sum of 3 quarters · filed 2023-08-08 | $55.48M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $13.40M 6-K · filed 2023-05-09 | $26.86M derived: sum of 2 quarters · filed 2023-05-09 | $41.66M derived: sum of 3 quarters · filed 2023-05-09 | $59.93M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $13.46M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $28.26M derived: sum of 2 quarters · filed 2023-03-15 | $46.53M derived: sum of 3 quarters · filed 2023-03-15 | $60.48M 20-F · filed 2023-03-15 |
| 2021-09-30 | $14.80M 6-K · filed 2022-11-08 | $33.06M derived: sum of 2 quarters · filed 2022-11-08 | $47.02M 6-K · filed 2022-11-08 | $62.43M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $18.27M 6-K · filed 2022-08-09 | $32.22M 6-K · filed 2022-08-09 | $47.63M derived: sum of 3 quarters · filed 2023-03-15 | $58.62M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | $13.95M 6-K · filed 2022-05-09 | $29.37M derived: sum of 2 quarters · filed 2023-03-15 | $40.35M derived: sum of 3 quarters · filed 2023-03-15 | $47.75M derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | $15.42M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $26.40M derived: sum of 2 quarters · filed 2023-03-15 | $33.80M derived: sum of 3 quarters · filed 2023-03-15 | $37.59M 20-F · filed 2023-03-15 |
| 2020-09-30 | $10.99M 6-K · filed 2021-11-02 | $18.38M derived: sum of 2 quarters · filed 2021-11-02 | $22.17M 6-K · filed 2021-11-02 | |
| 2020-06-30 | $7.39M 6-K · filed 2021-08-03 | $11.18M 6-K · filed 2021-08-03 | ||
| 2020-03-31 | $3.79M 6-K · filed 2021-05-06 | |||
| 2019-12-31 | $1.12M 20-F · filed 2022-03-17 | |||
| 2018-12-31 | $469.00K 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |